A study published in the Journal of Neuroscience (November 5, 2008; 28(45):11500–11510) investigated the effects of nicotinic acid (vitamin B3) in mice genetically engineered to develop brain changes that resemble Alzheimer’s disease in humans.
In this experiment, one group of these Alzheimer’s-prone mice and a separate group of normal mice received nicotinic acid added to their drinking water. A third group of genetically engineered mice served as controls and received no supplementation. The intervention continued for four months.
Study Findings
At the end of the study period, researchers observed several notable differences in the supplemented mice:
-
Increased levels of proteins that stabilize microtubules in brain cells
-
Reduced accumulation of phosphorylated tau, a form of tau protein associated with neurofibrillary tangles
-
Preserved memory performance in the Alzheimer’s-prone mice receiving nicotinic acid
In contrast, the genetically engineered mice that did not receive nicotinic acid showed significant memory impairment. Remarkably, the Alzheimer’s-prone mice given nicotinic acid performed as well as the normal mice on memory tasks.
Context
Microtubules are essential structural components within neurons and play a critical role in intracellular transport and neuronal stability. Disruption of microtubule-associated proteins and abnormal phosphorylation of tau are hallmark features of Alzheimer’s pathology.
This study suggests that nicotinic acid may influence neuronal structure and memory-related pathways in an animal model of Alzheimer’s disease. While the findings are compelling, they are limited to animal research and do not establish clinical benefit in humans.
